- Home
- NRO vs ACIU Comparison
NRO vs ACIU Comparison
Compare NRO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- ACIU
- Stock Information
- Founded
- NRO 2003
- ACIU 2003
- Country
- NRO United States
- ACIU Switzerland
- Employees
- NRO N/A
- ACIU N/A
- Industry
- NRO Finance/Investors Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- ACIU Health Care
- Exchange
- NRO Nasdaq
- ACIU Nasdaq
- Market Cap
- NRO 156.7M
- ACIU 168.7M
- IPO Year
- NRO N/A
- ACIU 2016
- Fundamental
- Price
- NRO $3.19
- ACIU $1.88
- Analyst Decision
- NRO
- ACIU Strong Buy
- Analyst Count
- NRO 0
- ACIU 1
- Target Price
- NRO N/A
- ACIU $12.00
- AVG Volume (30 Days)
- NRO 239.4K
- ACIU 115.4K
- Earning Date
- NRO 01-01-0001
- ACIU 08-05-2025
- Dividend Yield
- NRO 11.41%
- ACIU N/A
- EPS Growth
- NRO N/A
- ACIU N/A
- EPS
- NRO N/A
- ACIU N/A
- Revenue
- NRO N/A
- ACIU $32,014,254.00
- Revenue This Year
- NRO N/A
- ACIU N/A
- Revenue Next Year
- NRO N/A
- ACIU $533.21
- P/E Ratio
- NRO N/A
- ACIU N/A
- Revenue Growth
- NRO N/A
- ACIU 91.20
- 52 Week Low
- NRO $2.51
- ACIU $1.43
- 52 Week High
- NRO $3.45
- ACIU $4.41
- Technical
- Relative Strength Index (RSI)
- NRO 50.59
- ACIU 51.75
- Support Level
- NRO $3.15
- ACIU $1.83
- Resistance Level
- NRO $3.21
- ACIU $2.10
- Average True Range (ATR)
- NRO 0.04
- ACIU 0.15
- MACD
- NRO -0.00
- ACIU -0.00
- Stochastic Oscillator
- NRO 51.82
- ACIU 44.44
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.